Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. (PANTAX-Ib)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04652206 |
|
Recruitment Status :
Recruiting
First Posted : December 3, 2020
Last Update Posted : December 29, 2021
|
Sponsor:
Scandion Oncology A/S
Collaborator:
Alcedis GmbH
Information provided by (Responsible Party):
Scandion Oncology A/S
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 30, 2022 |
| Estimated Study Completion Date : | May 15, 2022 |